Welcome to our dedicated page for Portage Biotech news (Ticker: $PRTG), a resource for investors and traders seeking the latest updates and insights on Portage Biotech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Portage Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Portage Biotech's position in the market.
Rhea-AI Summary
Portage Biotech Inc. (PRTG) pauses adenosine clinical development to evaluate strategic alternatives and extend cash runway. Board of Directors halts ADPORT-601 trial enrollment for adenosine inhibitors PORT-6 and PORT-7.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9%
Tags
-
Rhea-AI Summary
Portage Biotech Inc. (PRTG) sells equity holding in Intensity Therapeutics for $2.8M, generating non-dilutive funding to support clinical trials and extend cash runway. The company plans to present interim data at ASCO Annual Meeting and final data at SITC Annual Meeting in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.73%
Tags
-
News
Rhea-AI Summary
Portage Biotech Inc. (PRTG) focuses on adenosine platform clinical development, with financial results reported for the fiscal quarter ended December 31, 2023. The company is advancing novel multi-targeted therapies for immuno-oncology, specifically the ADPORT-201 Phase 1a/1b clinical trial of PORT-6 and PORT-7 in selected solid tumors. Progress is seen with eight clinical sites enrolling patients, and updates are expected at the 2024 ASCO and SITC Annual Meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.71%
Tags
Rhea-AI Summary
Portage Biotech Inc. (NASDAQ: PRTG) announces the pause in iNKT clinical development to focus resources on adenosine clinical candidates. The company will evaluate a range of strategic options following a comprehensive review of its pipeline in the context of current capital raising market conditions. The ADPORT-201 adaptive Phase 1a/1b clinical trial of PORT-6 and PORT-7 has been progressing well, with strong interest from eight academic centers in the US. The phase 1a dose escalation portion of the trial is enrolling quickly, with no safety concerns at the doses evaluated so far. The company anticipates presenting data from this portion of the trial at a conference later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
-
Rhea-AI Summary
Portage Biotech Inc. (NASDAQ: PRTG) reported financial results for the fiscal quarter ended September 30, 2023. The company is focused on developing its two lead clinical programs, PORT-2 and PORT-6, and presented updated data at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting. The company also completed a $6 million financing in October 2023 for continued clinical development, general corporate, and working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Portage Biotech Inc. announced updates from its ongoing clinical trials of PORT-2 and PORT-6/PORT-7 for patients with non-small cell lung cancer (NSCLC) and melanoma. The data showed favorable safety and tolerability of PORT-2 as a monotherapy and in combination with KEYTRUDA®. The ADPORT-601 trial will evaluate PORT-6 and PORT-7 in tumors that overexpress adenosine, in combination with pembrolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
Rhea-AI Summary
Portage Biotech Inc. (NASDAQ: PRTG) announces a definitive agreement for the purchase and sale of 3,157,895 shares of common stock at $1.90 per share, with expected gross proceeds of approximately $6.0 million. The company will also issue unregistered warrants for the purchase of additional shares. The net proceeds will be used for clinical development and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
-
Rhea-AI Summary
Portage Biotech Inc. to participate in Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
-
Rhea-AI Summary
Portage Biotech Inc. enters clinical trial collaboration with Merck to evaluate its adenosine antagonists in combination with KEYTRUDA for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.81%
Tags
Rhea-AI Summary
Portage Biotech Inc. reports financial results for Q2 2023, focusing on clinical programs PORT-2, PORT-6, and PORT-7. Positive highlights include favorable interim data for PORT-2 showing monotherapy activity and reduction of target lesions. The company is expanding its clinical footprint to 17 sites to accelerate patient accrual. The Phase 1 portion of the trial is expected to have final data in Q1 2024. The first patient was dosed in the Phase 1a trial for PORT-6. Operating expenses increased by $0.9 million, primarily due to clinical trial costs and manufacturing costs associated with adenosine assets acquired in the Tarus acquisition. R&D costs increased by 89% to $3.6 million, while G&A expenses decreased by 36% to $1.4 million. The company had cash and cash equivalents of $7.7 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.36%
Tags
Portage Biotech Inc.
Nasdaq:PRTG
PRTG Rankings
PRTG Stock Data
6.21M
10.21M
38.82%
11.61%
0.03%
Crude Petroleum and Natural Gas Extraction
Mining, Quarrying, and Oil and Gas Extraction
United States of America
Tortola
About PRTG
portage biotech inc is a company based out of canada.